The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
REGULATORY
Daiichi Sankyo’s TROP2 ADC, AZ’s COVID Antibody, Mpox Med in Line for Japan Approval
A batch of new medicines cleared the review of a key Japanese health ministry panel on December 6, setting the stage for their official stamp of approval. The list includes Daiichi Sankyo’s new antibody drug conjugate (ADC) and AstraZeneca’s preventive…
To read the full story
Related Article
- AstraZeneca’s COVID Antibody, Daiichi’s TROP2 ADC, and More Up for Review on Dec. 6
November 25, 2024
- AstraZeneca Files Sipavibart for COVID-19 Prevention in Japan
July 29, 2024
- Janssen Files Bispecific Teclistamab for MM in Japan
May 23, 2024
- Amgen Files BiTE Drug Tarlatamab for Lung Cancer in Japan
May 16, 2024
- MSD Files Keytruda Plus Chemo for Endometrial Cancer in Japan
April 15, 2024
- Smallpox Drug TPOXX Filed in Japan after Govt Request
April 12, 2024
- Daiichi Sankyo’s TROP2 ADC Now under Review for Breast Cancer in Japan
March 15, 2024
- Chugai Submits Mosunetuzumab for Follicular Lymphoma in Japan
March 15, 2024
- Pfizer Submits Hemophilia Treatment Marstacimab in Japan
February 29, 2024
- Takeda Files Immunoglobulin Hyqvia in Japan
February 15, 2024
- Sanofi Files High-Dose Quadrivalent Flu Vaccine in Japan
December 20, 2023
REGULATORY
- Japan Approves Moderna RSV Vaccine, GSK’s ADC, and More
May 20, 2025
- Ex-Lawmakers’ Club Proposes CEA Overhaul, GDP-Linked Drug Spending
May 16, 2025
- Ex-PM Kishida Stresses Need to Bolster Innovation in Japan: Tokyo Speech
May 16, 2025
- Biktarvy Gets Label Update to Add Eligible Patients
May 16, 2025
- Regional Formulary Push Pops Up from Ishin at 3-Party Talks
May 16, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…